Hypoadeponectinemia linked to the metabolic syndrome
MedWire News: Low serum concentrations of adiponectin may play a significant role in the development of the metabolic syndrome, study findings suggest.
Jang-Young Kim and colleagues, from Yonsei University in Wonju, Korea, found significant associations between hypoadeponectinemia and the presence of the metabolic syndrome, as well as individual components of syndrome, in the study population.
Writing in the Yonsei Medical Journal, the researchers say their findings support the future use of adiponectin concentrations in predicting risk for cardiovascular disease.
The team analyzed data on nearly 6000 nondiabetic Korean adults (aged >40 years) who were enrolled in the Korean Genomic Rural Cohort between November 2005 and December 2006, and for whom medical data and measures of adiponectin concentrations were available.
Presence or absence of the metabolic syndrome was determined using a modified version of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP)-III criteria.
In all, the metabolic syndrome was present in 23.6% of men and 34.1% of women.
Median adiponectin levels were significantly lower in participants with the metabolic syndrome, compared with those without, at 6.0 versus 8.0 µg/ml in men, and 10.1 versus 11.7 µg/ml in women, respectively.
Furthermore, median levels of adiponectin significantly decreased with each additional component of the metabolic syndrome; the respective adiponectin levels for men with no, one, two, three, or at least four components were 8.9, 8.1, 7.3, 6.1, and 5.7 µg/ml, while those in women were 12.8, 12.0, 11.4, 10.7, and 9.4 µg/ml.
For both men and women, a decrease in the concentration of adiponectin was significantly associated with increases in waist circumference and levels of triglycerides, C-reactive protein (CRP), fasting glucose, and insulin, and decreases in high-density lipoprotein and age.
In addition, men and women in the highest adiponectin quartile (≥10.70 µg/ml for men and ≥14.6 µg/ml for women) were 68% and 43% less likely to have the metabolic syndrome than those in the lowest quartile (<5.18 µg/ml for men and <8.21 µg/ml for women), respectively, even after adjustment for age, body mass index, smoking, CRP, and lipid profiles.
The team therefore concludes that serum adiponectin is independently protective against the metabolic syndrome in both men and women.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2011
By Nikki Withers